Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2

Diabetologia

Volumn 61, Issue 10, 2018, Pages 2087-2097

  Ghezzi, Chiara ^a   Loo, Donald D F ^a   Wright, Ernest M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gliflozins; Glucose; GLUTs; Inhibitors; Kidney; Phlorizin; Proximal tubule; Review; SGLTs; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; PHLORIZIN; SLC2A2 PROTEIN, HUMAN; SLC5A1 PROTEIN, HUMAN; SLC5A2 PROTEIN, HUMAN;

AUTOSOMAL RECESSIVE DISORDER; CELL FUNCTION; CELLULAR DISTRIBUTION; FAMILIAL RENAL GLUCOSURIA; FANCONI BICKEL SYNDROME; GLUCOSE ABSORPTION; GLUCOSE GALACTOSE MALABSORPTION; GLUCOSE REABSORPTION; GLUCOSE TRANSPORT; HUMAN; KIDNEY; KIDNEY PROXIMAL TUBULE; MOLECULAR BIOLOGY; MOLECULAR CLONING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; ANIMAL; DRUG DESIGN; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSURIA; HEK293 CELL LINE; HOMEOSTASIS; KIDNEY TUBULE; KNOCKOUT MOUSE; METABOLISM; MOUSE; PHARMACOLOGY; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; GLUCOSE; GLUCOSE TRANSPORTER TYPE 2; GLYCOSURIA; HEK293 CELLS; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; KIDNEY TUBULES; KIDNEY TUBULES, PROXIMAL; MICE; MICE, KNOCKOUT; PHLORHIZIN; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85052134176     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-018-4656-5     Document Type: Review

References (52)

1. Chasis H, Jolliffe N, Smith HW (1933) The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man. J Clin Invest 12:1083–1090
2. Burg MB, Knepper MA (1986) Single tubule perfusion techniques. Kidney Int 30:166–170
3. Barfuss DW, Schafer JA (1981) Differences in active and passive glucose transport along the proximal nephron. Am J Phys 241:F322–F332
4. Schultz SG, Curran PF (1970) Coupled transport of sodium and organic solutes. Physiol Rev 50:637–718
5. Hopfer U, Nelson K, Perrotto J, Isselbacher KJ (1973) Glucose transport in isolated brush border membrane from rat small intestine. J Biol Chem 248:25–32
6. Wright EM, Loo DD, Hirayama BA (2011) Biology of human sodium glucose transporters. Physiol Rev 91:733–794
7. Fanconi G, Bickel H (1949) Chronic aminoaciduria (amino acid diabetes or nephrotic-glucosuric dwarfism) in glycogen storage and cystine disease. Helv Paediatr Acta 4:359–396 [article in German]
8. Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B, Schaub J (1997) Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet 17:324–326
9. Santer R, Groth S, Kinner M et al (2002) The mutation spectrum of the facilitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet 110:21–29
10. Mudaliar S, Polidori D, Zambrowicz B, Henry RR (2015) Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 38:2344–2353
11. Gallo LA, Wright EM, Vallon V (2015) Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res 12:78–89
12. Hediger MA, Coady MJ, Ikeda TS, Wright EM (1987) Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 330:379–381
13. Hediger MA, Turk E, Wright EM (1989) Homology of the human intestinal Na+/glucose and Escherichia coli Na+/proline cotransporters. Proc Natl Acad Sci U S A 86:5748–5752
14. Wells RG, Pajor AM, Kanai Y, Turk E, Wright EM, Hediger MA (1992) Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter. Am J Phys 263:F459–F465
15. Wright EM, Turk E (2004) The sodium/glucose cotransport family SLC5. Pflugers Arch 447:510–518
16. Wright EM (2013) Glucose transport families SLC5 and SLC50. Mol Asp Med 34:183–196
17. Nishimura M, Naito S (2005) Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet 20:452–477
18. Park J, Shrestha R, Qiu C et al (2018) Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease. Science 360:758–763
19. Faham S, Watanabe A, Besserer GM et al (2008) The crystal structure of a sodium galactose transporter reveals mechanistic insights into Na+/sugar symport. Science 321:810–814
20. Watanabe A, Choe S, Chaptal V et al (2010) The mechanism of sodium and substrate release from the binding pocket of vSGLT. Nature 468:988–991
21. Cramer SC, Pardridge WM, Hirayama BA, Wright EM (1992) Colocalization of GLUT2 glucose transporter, sodium/glucose cotransporter, and gamma-glutamyl transpeptidase in rat kidney with double-peroxidase immunocytochemistry. Diabetes 41:766–770
22. Balen D, Ljubojevic M, Breljak D et al (2008) Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody. Am J Phys Cell Phys 295:C475–C489
23. Sabolic I, Vrhovac I, Eror DB et al (2012) Expression of Na+−D-glucose cotransporter SGLT2 in rodents is kidney-specific and exhibits sex and species differences. Am J Phys Cell Phys 302:C1174–C1188
24. Vrhovac I, Balen Eror D, Klessen D et al (2015) Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467:1881–1898
25. Scafoglio C, Hirayama BA, Kepe V et al (2015) Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A 112:E4111–E4119
26. Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM (2011) Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Phys Cell Phys 300:C14–C21
27. Sala-Rabanal M, Hirayama BA, Ghezzi C et al (2016) Revisiting the physiological roles of SGLTs and GLUTs using positron emission tomography in mice. J Physiol 594:4425–4438
28. Powell DR, DaCosta CM, Gay J et al (2013) Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 304:E117–E130
29. Santer R, Kinner M, Lassen CL et al (2003) Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 14:2873–2882
30. Wright E (2009) Diseases of renal glucose handling. In: Lifton R, Somlo S, Giebisch GH, Seldin DW (eds) Genetic diseases of the kidney. Elsevier, New York, pp 131–140
31. Ghezzi C, Hirayama BA, Gorraitz E, Loo DD, Liang Y, Wright EM (2014) SGLT2 inhibitors act from the extracellular surface of the cell membrane. Phys Rep 2:e12058
32. Ghezzi C, Yu AS, Hirayama BA et al (2017) Dapagliflozin binds specifically to sodium-glucose cotransporter 2 in the proximal renal tubule. J Am Soc Nephrol 28:802–810
33. Hummel C, Lu C, Liu J et al (2012) Structural selectivity of human SGLT inhibitors. Am J Phys Cell Phys 302:C373–C382
34. Silverman M (1974) The in vivo localization of high-affinity phlorizin receptors to the brush border surface of the proximal tubule in dog kidney. Biochim Biophys Acta 339:92–102
35. Abramson J, Wright EM (2009) Structure and function of Na(+)-symporters with inverted repeats. Curr Opin Struct Biol 19:425–432
36. Yan N (2015) Structural biology of the major facilitator superfamily transporters. Annu Rev Biophys 44:257–283
37. Loo DD, Jiang X, Gorraitz E, Hirayama BA, Wright EM (2013) Functional identification and characterization of sodium binding sites in Na symporters. Proc Natl Acad Sci U S A 110:E4557–E4566
38. Adelman JL, Ghezzi C, Bisignano P et al (2016) Stochastic steps in secondary active sugar transport. Proc Natl Acad Sci U S A 113:E3960–E3966
39. Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397–404
40. Pajor AM, Randolph KM, Kerner SA, Smith CD (2008) Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters. J Pharmacol Exp Ther 324:985–991
41. Coady MJ, El Tarazi A, Santer R et al (2017) MAP17 is a necessary activator of renal Na+/glucose cotransporter SGLT2. J Am Soc Nephrol 28:85–93
42. Coady MJ, Wallendorff B, Lapointe JY (2017) Characterization of the transport activity of SGLT2/MAP17, the renal low-affinity Na+/glucose cotransporter. Am J Physiol Ren Physiol 313:F467–F474
43. Ghezzi C, Wright EM (2012) Regulation of the human Na+−dependent glucose cotransporter hSGLT2. Am J Phys Cell Phys 303:C348–C354
44. Hirsch JR, Loo DD, Wright EM (1996) Regulation of Na+/glucose cotransporter expression by protein kinases in Xenopus laevis oocytes. J Biol Chem 271:14740–14746
45. Turk E, Kim O, le Coutre J et al (2000) Molecular characterization of Vibrio parahaemolyticus vSGLT: a model for sodium-coupled sugar cotransporters. J Biol Chem 275:25711–25716
46. Sala-Rabanal M, Hirayama BA, Loo DD, Chaptal V, Abramson J, Wright EM (2012) Bridging the gap between structure and kinetics of human SGLT1. Am J Phys Cell Phys 302:C1293–C1305
47. Gorraitz E, Hirayama BA, Paz A, Wright EM, Loo DDF (2017) Active site voltage clamp fluorometry of the sodium glucose cotransporter hSGLT1. Proc Natl Acad Sci U S A 114:E9980–E9988
48. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21:31–38
49. Bisignano P, Kalyanaraman C, Ghezzi C et al (2017) Structural insights into sodium-dependent sugar transporters and their inhibition mechanism. Biophys J 128a:112 (abstract)
50. Wright EM, Martin MG, Turk E (2001) Familial glucose-galactose malabsorption and hereditary renal glycosuria. In: Scriver CR, Beaudet AL, Sly WS et al (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 4891–4908
51. Frohnert PP, Hohmann B, Zwiebel R, Baumann K (1970) Free flow micropuncture studies of glucose transport in the rat nephron. Pflugers Arch 315:66–85
52. Santer R, Calado J (2010) Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin J Am Soc Nephrol 5:133–141